DMT efficiently inhibits hepatic gluconeogenesis by regulating the Gαq signaling pathway

Ting-Ting Zhou1,2, Fei Ma3, Xiao-Fan Shi1,2, Xin Xu1,2, Te Du1,2, Xiao-Dan Guo1,2, Gai-Hong Wang1, Liang Yu1,2, Vatcharin Rukachaisirikul4, Li-Hong Hu1,2, Jing Chen1,2 and Xu Shen1,2,5

1Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
2University of Chinese Academy of Sciences, Beijing, China
3School of Pharmacy, East China University of Science and Technology, Shanghai, China
4Department of Chemistry, Faculty of Science, Prince of Songkla University, Songkhla, Thailand
5Key Laboratory of Drug Target and Drug for Degenerative Disease, School of Medicine and Life Sciences, Nanjing University of Chinese Medicine, Nanjing, China

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with complicated pathogenesis and targeting gluconeogenesis inhibition is a promising strategy for anti-diabetic drug discovery. G protein-coupled receptors (GPCRs) are classified as distinct families by heterotrimeric G proteins, primarily including Gαs, Gαi and Gαq. Gαs-coupled GPCRs function potently in the regulation of hepatic gluconeogenesis by activating cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and Gαi-coupled GPCRs exhibit inhibitory effect on adenylyl cyclase and reduce intracellular cAMP level. However, little is known about the regulation of Gαq-coupled GPCRs in hepatic gluconeogenesis. Here, small-molecule 2-(2,4-dimethoxy-3-methylphenyl)-7-(thiophen-2-yl)-9-(trifluoromethyl)-2,3-dihydropyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(1H)-one (DMT) was determined to suppress hepatic glucose production and reduce mRNA levels of gluconeogenic genes. Treatment of DMT in db/db mice decreased fasting blood glucose and hemoglobin A1C (HbA1c) levels, while improved glucose tolerance and pyruvate tolerance. Mechanism study demonstrated that DMT-inhibited gluconeogenesis by regulating the Gαq/phospholipase C (PLC)/inositol-1,4,5-triphosphate receptor (IP3R)-mediated calcium (Ca2+)/calmodulin (CaM)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (AKT)/forkhead box protein 01 (FOXO1) signaling pathway. To our knowledge, DMT might be the first reported small molecule able to suppress hepatic gluconeogenesis by regulating Gαq signaling, and our current work has also highlighted the potential of DMT in the treatment of T2DM.

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, insulin resistance and relative lack of insulin (An & He 2016). T2DM accounts for over 90% of diabetes cases, and its incidence has dramatically increased over the past few decades (Shaw et al. 2010, An & He 2016). Although dozens of
clinical drugs are currently used for treating T2DM, their varied side effects are commonly determined, such as hypoglycemia, gastrointestinal disturbances, edema, weight gain and lactic acidosis (Moller 2001, Xu et al. 2014). For example, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newly injectable peptide drugs used for the treatment of hyperglycemia (Scheen 2016). They are known for improving glycemic control with low risk of hypoglycemia, and even reducing cardiovascular disease risk (Dalsgaard et al. 2017). However, GLP-1 RAs are associated with gastrointestinal disturbance events, including nausea and vomiting (Peng et al. 2016). GLP-1 RAs may also potentially contribute to the development of pancreatitis and increase the risk of pancreatic cancer (Lamont & Andrikopoulos 2014). Thus, it is still urgent to develop new drugs based on new targets or signal(s) against T2DM.

Pathologically, endogenous glucose production from uncontrolled hepatic gluconeogenesis is a major source of fasting hyperglycemia in T2DM patients (An & He 2016), and metformin is being widely used as a first-line oral hypoglycemic drug to treat T2DM. Considering that the hypoglycemic mechanism of metformin is generally believed to be related to its ability in hepatic gluconeogenesis suppression (Inzucchi et al. 1998, An & He 2016), appropriate control of hepatic gluconeogenesis is always an attractive strategy for the treatment and prevention of T2DM.

Gluconeogenesis is a metabolic process responsible for glucose generation from certain non-carbohydrate carbon substrates, such as pyruvate, lactate, lipids, glycerol and glucogenic amino acids (Jitrapakdee 2012). In this process, glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) function as the key rate-limiting regulatory enzymes (Rui 2014). Gluconeogenesis occurs principally in liver and plays an important role in maintaining blood glucose level to avoid hypoglycemia during prolonged starvation (Jitrapakdee 2012). However, patients with T2DM have continuous activated gluconeogenesis and elevated blood glucose level (Yoon et al. 2001).

Hepatic gluconeogenesis is highly regulated by hormonal systems in response to fasted and fed states (Jitrapakdee 2012). Insulin suppresses gluconeogenesis through insulin receptor (IR)/IR substrates (IRSs)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) pathway (Saltiel & Kahn 2001, Rui 2014). Additionally, insulin also suppresses gluconeogenesis by activating salt-inducible kinase 2 (SIK2) leading to cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB)-regulated transcriptional coactivator 2 (CRTC2) phosphorylation and cytoplasmic translocation (Dentin et al. 2007). Glucagon binds to glucagon receptor (GCCR), a G protein-coupled receptor (GPCR), and activates Gas/cAMP/protein kinase A (PKA)/CREB/CRTC2 signaling pathway to stimulate gluconeogenesis (Jiang & Zhang 2003). Activated PKA phosphorylates CREB and promotes CRTC2 dephosphorylation and nuclear transportation (Liu et al. 2008) and also activates inositol-1,4,5-triphosphate receptor (IP3R) to increase calcium (Ca++) release from endoplasmic reticulum (ER) into cytoplasm resulting in the calcineurin-mediated dephosphorylation of CRTC2 (Wang et al. 2012).

GPCRs occupy the largest family of receptors in mammalian genome and are classified as distinct families by heterotrimeric G proteins, primarily including Gas, Gdi and Gq (Mitchell 2013). GCCR is abundantly expressed in hepatocytes and positively regulates hepatic gluconeogenesis by activating adenyl cyclase to stimulate cAMP/PKA pathway in a Gas-dependent manner (Cho et al. 2012), while Gai-coupled GPCRs negatively regulate gluconeogenesis by inactivating adenyl cyclase (Li et al. 2013). However, little is known about the metabolic functions of GPCRs coupled to Gq protein in liver.

In the current study, we reported that small molecular compound 2-(2,4-dimethoxy-3-methylphenyl)-7-(thiophen-2-yl)-9-(trifluoromethyl)-2,3-dihydropyrido[3′,2′:4,5]thieno[3,2-d]pyrimidin-4(1H)-one (DMT, Fig. 1A) antagonized the glucagon-stimulated hepatic gluconeogenesis by regulating the Gq/phospholipase C (PLC)/IP3R-mediated Ca2+/calmodulin (CaM)/PI3K/AKT/forkhead box protein O1 (FOXO1) signaling pathway. Assay on T2DM model db/db mice demonstrated that DMT administration efficiently decreased fasting blood glucose and hemoglobin A1c (HbA1c) levels and improved glucose tolerance and pyruvate tolerance tests. To our knowledge, DMT might be the first reported small molecule as a Gaq signaling regulator with the inhibitory effect on hepatic gluconeogenesis, and the relevant mechanism has been intensively investigated. Moreover, the high efficiency of DMT in improving glucose homeostasis of diabetic mice has highlighted the potential of this agent in the treatment of T2DM.
DMT inhibits hepatic gluconeogenesis. (A) Chemical structure of DMT. (B) Primary hepatocytes were treated as indicated, and HGP assay was performed according to the published approach (Zhang et al. 2013). Glucagon (10nM) was used to mimic hyperglucagonemia stimulating excessive gluconeogenesis, and metformin (2mM) was used as a positive control. (C) DMT (1, 10, 20µM) inhibited HGP. (D) Metformin (20µM) did not change the HGP induced by glucagon. (E, F, G and H) Primary hepatocytes were treated with DMT (1, 10, 20µM) for 24h, followed by stimulation with glucagon (10nM) together for another 2h, and collected for q-PCR assay to determine the mRNA levels of gluconeogenic genes G6pase, Pepck, Fbp2 and Pgc1α. All data were obtained from three independent experiments and presented as means ± s.e.m. (**P < 0.01, ***P < 0.001; ns, no significance).

Materials and methods

Materials and reagents

Glucagon, forskolin (FSK), 2-aminoethoxydiphenyl borate (2-APB), 3-isobutyl-1-methylxanthine (IBMX), pertussis toxin (PTX), collagenase and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7) were purchased from Sigma-Aldrich. U73122 and wortmannin were from Selleck Chemicals (Shanghai, China). Suramin was from J&K Chemical Ltd. (Shanghai, China). DMT was from commercial compound library (SPECS, Holland). Antibodies against phospho-AKT (Ser473), AKT, phospho-IR (Tyr1135/1136), IR, phospho-FOXO1 (Ser256), FOXO1, phospho-CREB (Ser133), CREB, phospho-S' adenosine monophosphate-activated protein kinase (AMPK) (Thr172), AMPK and Lamin B1 were from Cell Signaling Technology, G6Pase, PEPCK and Gαq was from Santa Cruz Biotechnology and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Kangcheng Bio-tech (Shanghai, China). Gaq-siRNA was purchased from Santa Cruz Biotechnology. Transfection reagent Lipofectamine RNAiMAX was from Invitrogen Company. All media for cell culture, fetal bovine serum (FBS) and antibiotic supplements were from Invitrogen Company. Fluo-4 AM was from Life Technology.

**Isolation of mouse primary hepatocytes**

Primary hepatocytes were isolated from 9-week-old male C57BL/6 mice fasted overnight with water *ad libitum* by a two-step collagenase perfusion method as previously described with modification (Mathijs *et al.* 2009). Briefly, before isolation, mice were pre-anesthetized and the abdominal cavity and thoracic cavity were opened. The liver was perfused with clear cannulation inserted into the thoracic inferior vena cava and secured with a ligature. The abdominal hepatic inferior vena cava was occluded with forceps and portal vein was cut through allowing outflow of the solution. The liver was perfused with 0.5 mM EGTA-contained phosphate buffered saline (PBS) buffer for about 5 min, and the Dulbecco’s modified eagle medium (DMEM) supplemented with collagenase (0.5 mg/mL) was then replaced for 5–10 min. The perfusion velocity was 3 mL/min for the first step and 6 mL/min for the second. The temperature around 37°C was maintained for the entire procedure of perfusion. The swollen liver was rapidly excised from the body cavity and was transferred to an iced sterile petri dish after finishing the perfusion. The gall bladder and needless fascia were removed from the softened liver. The cells were released by disrupting the liver capsule mechanically into iced standard Williams’ E medium (containing 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin). The cells were isolated from undigested tissue with a sterile 70-µm mesh nylon filter. After centrifugation (700g/min) at 4°C for 5 min, cells were re-suspended by standard Williams’ E medium with 50% Percoll solution and underwent a second centrifugation at 1000g/min for 10 min to remove dead or low-viability cells. Freshly isolated mouse hepatocytes were seeded at a density of 1.2 million cells per well onto 6-well plates (for quantitative real-time PCR (q-PCR) assay), 0.5 million per well onto 12-well plates (for Western blot assay) or 50,000 per well onto 48-well plates (for hepatic glucose production (HGP) assay) in standard Williams’ E medium.

**HGP assay**

HGP assay was conducted according to the previous study with modification (Zhang *et al.* 2013). In the assay, freshly isolated mouse hepatocytes were seeded onto 48-well plates with standard Williams’ E medium. After 4-h attachment, cells were changed to serum-free minimum essential medium (MEM) and incubated with corresponding compounds and 10nM glucagon for 16h. After washing with PBS twice to remove the remaining glucose, cells were incubated with compounds and 10nM glucagon in 200µL glucose production detection buffer (glucose-free DMEM without phenol red containing 20mM sodium lactate and 2mM sodium pyruvate). After 6-h incubation, 50µL detection buffer was collected for glucose concentration measurement with a colorimetric glucose assay kit (Nanjing Jiancheng, Nanjing, China) according to the manufacturer’s instruction. The results were normalized to the total protein concentration measured by BCA protein kit (Thermo Scientific).

**RNA isolation and q-PCR assay**

Primary hepatocytes were seeded onto 6-well plates. After 4-h attachment, cells were replaced to MEM supplemented with 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin. Cells were incubated with corresponding compounds for 24 h and stimulated with 10nM glucagon together for another 2 h. Total RNA from cultured mouse hepatocytes or mashed liver tissues was extracted using TRIzol reagent according to the manufacturer’s protocol (Takara Bio). Complementary DNAs were generated by PrimeScript RT reagent kit (Takara Bio) and analyzed by q-PCR assay using SYBR Premix Ex Taq (Takara Bio) on a Bio-Rad CFX Connect Real-Time System (Bio-Rad Company). The mRNA levels of specific genes were normalized to *Gapdh*. The primers for q-PCR were generated from Sangon Biotech (Shanghai, China) as follows:

- **G6pase (+)**, TAATGGCTCTGCCAATGGCGATC; **G6pase (−)**, ATCAGTCTGTGCCCTTGCCCCTGT;
- **Pepck (+)**, CTGCAAAACGGTTCTGAGCTTC; **Pepck(−)**, CAGCAACTGCGCTTCTCC;
- Peroxisome proliferator γ-activated receptor coactivator 1-α (*Pgc1α*) (+), TCTCTGGGTGATTGAAGTGGTC; *Pgc1α* (−), TGTCAATCGCATCAATGAGGGC;
- Fructose bisphosphatase 2 (*Fbp2*) (+), ACGCCTACGTATGGAAAAAGG;
Intracellular Ca\(^{2+}\) level assay
Intracellular Ca\(^{2+}\) level assay was performed as previously described with modification (Yao et al. 2015). Primary hepatocytes were seeded onto 96-well plates at a density of 20,000 cells per well and incubated overnight. Cells were loaded with 40\muL of Ca\(^{2+}\) dye (Fluo-4 AM, 2\muM) and then incubated at 37°C for 40 min. Intracellular Ca\(^{2+}\) level was analyzed by FlexStation II 384 (Molecular Devices, CA, USA) at an excitation wavelength of 490nm and emission wavelength of 525 nm. After the baseline fluorescence signals were measured for the first 16 s, the corresponding compounds in Hank’s balanced salt solution (HBSS) buffer were added to the plate through an automated pipette. Ca\(^{2+}\)-free HBSS buffer was used to mimic the extracellular Ca\(^{2+}\)-free situation. The relative fluorescence signals were measured at 1.6-s intervals for 80 s, and the data were analyzed and shown as the area under the curve (AUC).

Nuclear and cytosolic protein extraction
Nuclear and cytosolic protein was extracted by the nucleus and cytoplasm extraction kit (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instruction. Briefly, primary hepatocytes were incubated with cytosol reagent A supplemented with PMSF on ice for 15 min, and then cytosol reagent B was added, followed by centrifugation to obtain the cytoplasmic protein in the liquid supernatant. The precipitate was re-suspended in nuclear protein extracting solution supplemented with PMSF, followed by vortex and centrifugation to obtain nuclear protein. The contents of nuclear and cytoplasmic protein were measured by BCA protein assay kit (Thermo Scientific).

Western blot assay
Western blot assays were performed as previously described (Zhou et al. 2016). Cell or tissue lysate was separated by SDS-PAGE and transferred to the nitrocellulose membrane (GE Health). Membranes were blocked for 1 h in 5% nonfat milk and incubated with corresponding primary antibodies at 4°C overnight. All membranes were subsequently incubated with secondary antibodies for 2 h at room temperature. Membranes were visualized using the West-Dura detection system (Thermo Scientific). The signal was collected by ImageQuant LAS 4000 mini (GE Health).

Intracellular cAMP assay
Primary hepatocytes were seeded onto 96-well plates at a density of 20,000 cells per well and incubated overnight. Cells were treated with corresponding compounds, 3-isobutyl-1-methylxanthine (IBMX) (500\muM) and stimulated with/without FSK (10\muM) or glucagon (10nM) for 30 min. Intracellular CAMP levels were detected by cAMP-Glo assay kit (Promega).

Whole-cell GCGR-binding assay
Whole-cell GCGR-binding assay was performed as described previously (Siu et al. 2013). CHO-K1 cells were seeded onto 96-well poly-1-lysine-treated cell culture plates (PerkinElmer). After overnight culture, the cells were transiently transfected with human GCGR DNA. After 24-h transfection, cells were incubated with blocking buffer (F12 supplemented with 33 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 0.1% bovine serum albumin (BSA), pH 7.4) for 2 h at 37°C, and then incubated with \(^{125}\)I-glucagon (40 PM) and different concentrations of unlabeled glucagon or DMT at room temperature for 3 h. Cells were then washed three times with ice-cold PBS and lysed by 50\muL lysis buffer (PBS supplemented with 20mM Tris–HCl and 1% Triton X-100, pH 7.4). The radioactivity was counted (counts per minute, CPM) in a scintillation counter (MicroBeta2 Plate Counter, PerkinElmer) using a scintillation cocktail (OptiPhase SuperMix, PerkinElmer).

Animal experiments
All animals were received humane care, and animal-related protocols were approved by the Institutional Animal Care and Use Committees at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. \(db/db\) male mice (BKS.Cg-Dock\(^7\) +/+ Lepr\(^db/db\)) were from Jackson Laboratory. Eight-week-old male mice were housed (\(n=2–3\) per cage) at relative humidity of 50% and a 12-h-light-darkness cycle at 20–22°C, and given \textit{ad libitum}...
access to water and food. Mice were divided into 2 groups by fasting blood glucose and body weight. Vehicle or DMT (25mg/kg) was administrated by intraperitoneal injection daily for 5 weeks. Fasting blood glucose levels from 6-h fasted mice were measured weekly, and body weight was recorded twice per week. At the termination of the assay, mice were killed and liver tissues were stored at −80°C for analysis. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of plasma in db/db mice were analyzed with an automatic analyzer (Hitachi 7020, Hitachi).

Oral glucose tolerance test (OGTT) For the glucose tolerance test, the mice were fasted for 16h at the fourth week, 1.5g/kg glucose was administered orally with a gavage needle. Glucose levels were measured from tail vein blood samples at 0, 15, 30, 60, 90 and 120min by ACCU-CHEK active blood sugar system (Roche).

Pyruvate tolerance test (PTT) For the pyruvate tolerance test, the mice were fasted for 16h at the fifth week and then injected intraperitoneally with sodium pyruvate (1.5g/kg). Blood glucose levels were measured with tail vein blood samples at 0, 15, 30, 60, 90 and 120min.

Preliminary pharmacokinetic and tissue distribution assay

18–20g-weight male C57BL/6 mice (n=3) were used for pharmacokinetic study. In the assay, mice were treated with DMT (10mg/kg) by intraperitoneal injection, and the contents of DMT in plasma were then detected at 0.08, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72 and 168h, and data were analyzed with WinNonlin6.4 software to get pharmacokinetic parameters. For tissue distribution assay, 18–20g-weight male C57BL/6 mice (n=4) were treated with DMT (10mg/kg) by intraperitoneal injection. After 4-h treatment, the mice were killed and blood and organs related to glucose homeostasis, including liver, pancreas and gastrocnemius muscle tissues, were stored to detect the contents of DMT.

Statistical analysis

Significant differences of two groups were compared using Student’s t test (unpaired, two tailed), and multiple treatment groups were compared within individual experiments by ANOVA test with GraphPad Prism 5 software. All values were presented as mean±s.e.m. P value <0.05 was considered statistically significant. Significant differences were shown as P<0.05: *, P<0.01: **, P<0.001: ***. Unless otherwise indicated, all experiments were repeated at least three times.

Results

DMT inhibits hepatic gluconeogenesis

In the current work, we constructed a screening platform against the lab in-house compound library for assaying the agents able to inhibit HGP from gluconeogenesis with long-time fasting in primary hepatocytes. Given that stimulation of HGP is sustained during long duration of hyperglucagonemia when insulin secretion is inhibited in healthy lean males (Chakravarthy et al. 2017), we incubated with glucagon (10nM) for long time to mimic the pathological state of hyperglucagonemia and stimulate excessive gluconeogenesis in HGP assay. In the assay, sodium lactate (20mM) and sodium pyruvate (2mM) were used as gluconeogenic substrates, and compounds (20µM) were used for screening. The results indicated that metformin (2µM) as a positive control suppressed HGP (Fig. 1B) and DMT (1, 10, 20µM) efficiently antagonized the glucagon-stimulated increase in HGP (Fig. 1C). Additionally, metformin (20µM) could not reduce HGP (Fig. 1D), indicating more potency of DMT than metformin. Moreover, incubation of DMT with glucagon obviously reduced the mRNA levels of gluconeogenic genes G6pase, Pepck, Fbp2 and Pgc1α compared with glucagon treatment results (Fig. 1E, F, G and H). Finally, HGP assay involving glucagon (100nM) for 5h was also conducted as previously described (Rah & Kim 2015), and the result (Supplementary Fig. 1A, see section on supplementary data given at the end of this article) indicated that DMT still inhibited the glucagon-induced HGP. Thus, all results demonstrated that DMT inhibits hepatic gluconeogenesis.

DMT represses hepatic gluconeogenesis through Ca2+/CaM/Pi3K/AKT/FOXO1 pathway

DMT inhibits gluconeogenesis independently of GCGR In view of the fact that GCGR antagonists function potently in repressing hepatic gluconeogenesis (Rivera et al. 2007, Xiong et al. 2012) and DMT antagonized the glucagon-stimulated HGP and gluconeogenic genes transcription, we at first investigated whether DMT functioned as a GCGR antagonist. As shown in Fig. 2A,
Figure 2
DMT inhibits gluconeogenesis through insulin-independent PI3K/AKT pathway. (A) Different concentrations of glucagon or DMT were performed with whole-cell GCGR binding assay. Glucagon was used as a positive control. (B) Primary hepatocytes were treated with DMT (1, 10, 20 µM) for 4 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (C) Relative levels of p-AKT/AKT in (B) from three independent experiments. (D) Primary hepatocytes were incubated with DMT (1, 10, 20 µM) for 4 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (E) Relative levels of p-CREB/CREB in (D) from three independent experiments. (F) Relative levels of p-AMPK/AMPK in (D) from three independent experiments. (G) Primary hepatocytes were treated with DMT (1, 10, 20 µM) and wortmannin (1 µM) for 4 h, and then collected for Western blot assay with antibodies against p-IR and IR. (H) Relative levels of p-IR/IR in (G) from three independent experiments. (I) Primary hepatocytes were cultured with DMT (1, 10, 20 µM) for 3.5 h, followed by co-incubation with glucagon (10 nM) for another 0.5 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (J) Relative levels of p-AKT/AKT in (I) from three independent experiments. (K) Primary hepatocytes were treated with PI3K inhibitor wortmannin (1 µM) and DMT (20 µM) for 4 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (L) Relative levels of p-AKT/AKT in (K) from three independent experiments. (M) Primary hepatocytes were pre-incubated with DMT (20 µM) and wortmannin (1 µM) for 3.5 h, followed by stimulation with glucagon (10 nM) for another 0.5 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (N) Relative levels of p-AKT/AKT in (M) from three independent experiments. (O) HGP assay involving wortmannin (1 µM) was performed as indicated. (P, Q and R) Primary hepatocytes were treated with DMT (20 µM) and wortmannin (1 µM) for 24 h, followed by stimulation with glucagon (10 nM) for another 2 h, and then q-PCR assay was carried out to detect the corresponding mRNA levels of gluconeogenic genes. All data were obtained from three independent experiments and presented as mean ± S.E.M. (**P < 0.01, ***P < 0.001; ns, no significance).
the whole-cell GCGR-binding assay demonstrated that DMT had no affinity against human GCGR (glucagon as a positive control). This result thus indicated that DMT is not a GCGR antagonist and the inhibition of DMT against gluconeogenesis is independent of GCGR.

**DMT inhibits gluconeogenesis through insulin-independent PI3K/AKT pathway** Given that PI3K/AKT and CAMP/PKA pathways are involved in the insulin/glucagon-regulated hepatic gluconeogenesis (Jiang & Zhang 2003, Wang et al. 2010) and activated AMPK inhibits hepatic gluconeogenesis by regulating CRT2 phosphorylation and nuclear translocation (Lee et al. 2010), we next investigated the potential of DMT in the regulation of the key proteins involved in these pathways in primary hepatocytes. The results indicated that treatment of DMT for 4h obviously increased AKT phosphorylation (Fig. 2B and C) but rendered no effects on the phosphorylation of CREB (a downstream protein of cAMP/PKA pathway) or AMPK (Fig. 2D, E and F). Notably, the effect of DMT (20µM) treated in different times (from 0.5 to 12h) on AKT phosphorylation (Supplementary Fig. 1B and C) suggested that the incubation time of DMT was set to 4h. In addition, DMT phosphorylated AKT in the absence of insulin (Fig. 2B and C) and did not phosphorylate IR (Fig. 2G and H), which thereby indicated that DMT activated AKT phosphorylation independently of insulin. Considering that DMT suppressed glucagon-induced hepatic gluconeogenesis, we next detected its potential effect on AKT phosphorylation in the presence of glucagon. As shown in Fig. 2I and J, pre-incubation of DMT for 3.5h and stimulation with glucagon together for another 0.5h effectively increased phosphorylated AKT compared with glucagon treatment. However, PI3K inhibitor wortmannin (Walker et al. 2000) antagonized the DMT-induced AKT phosphorylation either in the absence (Fig. 2K and L) or presence (Fig. 2M and N) of glucagon and restrained the DMT-inhibited HGP (Fig. 2O). In addition, wortmannin blocked the inhibition of DMT against the glucagon-induced gluconeogenic genes transcription (Fig. 2P, Q and R). Therefore, all results suggested that DMT inhibits gluconeogenesis by insulin-independent PI3K/AKT pathway.

**FOXO1 is the downstream of DMT-regulated PI3K/AKT pathway** FOXO1 as a transcription factor binds directly to the promoters of gluconeogenic genes to increase glucose production (Puigserver et al. 2003, Schilling et al. 2006) and is inactivated by AKT activation and detained in cytoplasm (Rui 2014). We thus investigated whether FOXO1 was involved in the regulation of DMT. Herein, we found DMT had no effect on mRNA level of FOXO1 (Fig. 3A), but dose dependently stimulated Foxo1 phosphorylation in the absence or presence of glucagon (Fig. 3B, C, D and E). As shown in Fig. 3F, G and H, the results demonstrated that phosphorylated FOXO1 was detained in cytoplasm. Moreover, wortmannin diminished such effects of DMT on FOXO1 phosphorylation (Fig. 3I, J, K and L). Therefore, these results indicated that FOXO1 is the downstream of DMT-regulated PI3K/AKT pathway.

**Ca²⁺/CaM axis is the upstream of DMT-regulated PI3K/AKT pathway** As IR has been found to be not involved in the pathway for DMT-mediated AKT phosphorylation, we next explored the upstream of PI3K/AKT pathway. It is reported that Ca²⁺ as a widespread second messenger controls a variety of cellular processes (Baba & Kuroasaki 2016, Dubois et al. 2016), and calmodulin (CaM) as a loop-helix-loop Ca²⁺-binding protein is a downstream transducer of Ca²⁺ responsible for regulating multiple processes in eukaryotic cells (Chin & Means 2000). For example, cytosolic free Ca²⁺ binds to CaM and activates PI3K by direct association with its p85 regulatory subunit resulting in AKT activation (Perez-Garcia et al. 2004, Xu et al. 2007). With these facts, we thus detected the effect of DMT on intracellular Ca²⁺ level. Interestingly, we found that DMT dose-dependently increased intracellular Ca²⁺ level (Fig. 4A). It is believed that the increase of cytosolic Ca²⁺ was possibly attributed to Ca²⁺ release from Ca²⁺ store rather than Ca²⁺ influx because DMT still increased cytosolic Ca²⁺ in extracellular Ca²⁺-free situation (Fig. 4B) and such an effect could be abolished by IP3R (a Ca²⁺-release channel in ER) antagonist 2-aminoethoxydiphenyl borate (2-APB) (Ansari et al. 2014) (Fig. 4C).

As shown in Fig. 4D, E, F and G, CaM antagonist W-7 (Bautista-Carbajal et al. 2017) blocked the DMT-stimulated increase of AKT phosphorylation in the absence or presence of glucagon, these results thus indicated that the intracellular DMT-mediated Ca²⁺/CaM axis likely regulated gluconeogenesis through PI3K/AKT pathway. To further verify such regulation, HGP- and q-PCR-related assays were carried out involving W-7. The results demonstrated that W-7 impaired the inhibition of DMT against glucose production (Fig. 4H) and mRNA levels of gluconeogenic genes (Fig. 4I, J and K). These results thereby confirmed that the DMT-induced inhibition against gluconeogenesis involved CaM regulation, further suggesting that
Figure 3
FOXO1 is the downstream of DMT-regulated PI3K/AKT pathway. (A) Primary hepatocytes were cultured with DMT (1, 10, 20 μM) for 24 h, followed by co-incubation with glucagon (10 nM) for another 2 h, and then collected for q-PCR assay to detect the mRNA levels of Foxo1. (B) Primary hepatocytes were treated with DMT (1, 10, 20 μM) for 4 h, and then collected for Western blot assay with antibodies against p-FOXO1 and FOXO1. (C) Relative levels of p-FOXO1/FOXO1 in (B) from three independent experiments. (D) Primary hepatocytes were cultured with DMT (1, 10, 20 μM) for 3.5 h, followed by co-incubation with glucagon (10 nM) for another 0.5 h, and then collected for Western blot assay with antibodies against p-FOXO1 and FOXO1. (E) Relative levels of p-FOXO1/FOXO1 in (D) from three independent experiments. (F) Primary hepatocytes were incubated with DMT (20 μM) for 4 h, followed by extraction of nuclear and cytoplasmic protein, and then collected for Western blot assay with antibodies against p-FOXO1 and FOXO1. (G and H) Relative levels of p-FOXO1/GAPDH in cytoplasm (G) and p-FOXO1/Lamin B1 in nucleus (H) from three independent experiments. (I) Primary hepatocytes were incubated with DMT (20 μM) and wortmannin (1 μM) for 4 h, and then collected for Western blot assay with antibodies against p-FOXO1 and FOXO1. (J) Relative levels of p-FOXO1/FOXO1 in (I) from three independent experiments. (K) Primary hepatocytes were pre-incubated with DMT (20 μM) and wortmannin (1 μM) for 3.5 h, followed by stimulation with glucagon (10 nM) for another 0.5 h, and then collected for Western blot assay with antibodies against p-FOXO1 and FOXO1. (L) Relative levels of p-FOXO1/FOXO1 in (K) from three independent experiments. All data were obtained from three independent experiments and presented as means ± s.e.m. (***P < 0.01, ****P < 0.001; ns, no significance).
Ca\(^{2+}\)/CaM axis is the upstream of DMT-regulated PI3K/AKT pathway. (A) Intracellular Ca\(^{2+}\) level of primary hepatocytes was detected with FlexStation II for 4 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (E) Relative levels of p-AKT/AKT in (D) from three independent experiments. (G) Relative mRNA levels of corresponding gluconeogenic genes. All data were obtained from three independent experiments and presented as means \(\pm\) s.e.m. (*P < 0.05, **P < 0.01, ***P < 0.001; ns, no significance).
Ca\textsuperscript{2+}/CaM axis is the upstream of the DMT-regulated PI3K/AKT pathway.

Taken together, all above-mentioned results fully indicated that DMT represses hepatic gluconeogenesis through Ca\textsuperscript{2+}/CaM/PI3K/AKT/FOXO1 pathway.

### DMT inhibits hepatic gluconeogenesis involving Guq/PLC/IP3R pathway

**PLC/IP3R axis is involved in DMT-regulated hepatic gluconeogenesis** It has been reported that IP3R as a Ca\textsuperscript{2+}-release channel is necessary for controlling multiple physiological processes through mediating the release of Ca\textsuperscript{2+} from ER (Bosanac et al. 2002, Mikoshiba 2015). Phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 1,4,5-trisphosphate (IP3) leading to the activation of IP3R and release of Ca\textsuperscript{2+} from ER (Kohn et al. 2015). Given that IP3R antagonist 2-APB alleviated DMT-induced increase in intracellular Ca\textsuperscript{2+} level (Fig. 3C), we next investigated whether PLC/IP3R axis was involved in the mediation of DMT on AKT phosphorylation. As expected,

### Figure 5

PLC/IP3R axis is involved in DMT-regulated hepatic gluconeogenesis. (A) Primary hepatocytes were incubated with DMT (20\textmu M) and IP3R antagonist 2-APB (50\textmu M) for 4h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (B) Relative levels of p-AKT/AKT in (A) from three independent experiments. (C) Primary hepatocytes were pre-incubated with DMT (20\textmu M) and 2-APB (50\textmu M) for 3.5h, followed by co-incubation with glucagon (10nM) for another 0.5h, and then collected for Western blot assay using antibodies against p-AKT and AKT. (D) Relative levels of p-AKT/AKT in (C) from three independent experiments. (E) Primary hepatocytes were incubated with DMT (20\textmu M) and PLC inhibitor U73122 (20\textmu M) for 4h, and then collected for Western blot assay using antibodies against p-AKT and AKT. (F) Relative levels of p-AKT/AKT in (E) from three independent experiments. (G) Primary hepatocytes were pre-incubated with DMT (20\textmu M) and U73122 (20\textmu M) for 3.5h, followed by co-incubation with glucagon (10nM) for another 0.5h, and then collected for Western blot assay using antibodies against p-AKT and AKT. (H) Relative levels of p-AKT/AKT in (G) from three independent experiments. (I) HGP assay involving 2-APB (50\textmu M) was performed as indicated. (J) HGP assay involving U73122 (20\textmu M) was performed as indicated. All data were obtained from three independent experiments and presented as means±s.e.m. (*P<0.05, **P<0.01, ***P<0.001; ns, no significance).

http://jme.endocrinology-journals.org DOI: 10.1530/JME-17-0121 © 2017 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 08/03/2019 01:52:50AM via free access
Figure 6

Gaq protein is involved in DMT-regulated AKT phosphorylation. (A) Primary hepatocytes were co-incubated with DMT (1, 10, 20 µM) and IBMX (500 µM) for 0.5 h, and then relative cellular cAMP concentrations were detected following the instructions. (B) Primary hepatocytes were co-incubated with DMT (1, 10, 20 µM), IBMX (500 µM) and glucagon (10 nM) for 0.5 h, and then relative cellular cAMP concentrations were detected following the instructions. (C) Primary hepatocytes were co-incubated with DMT (1, 10, 20 µM) for 0.5 h, and then relative cellular cAMP concentrations were detected following the instructions. (D) Primary hepatocytes were pre-incubated with PTX (50, 100, 200, 400 ng/mL) for 2 h, followed by co-incubation with DMT (20 µM) for another 4 h, and then collected for Western blot assay with antibodies against p-AKT and AKT. (E) Relative levels of p-AKT/AKT in (D) from three independent experiments. (F) Primary hepatocytes were transfected with Gaq-siRNA for 48 h, then cultured with DMT (20 µM) for 4 h, and finally collected for Western blot assay with antibodies against p-AKT and AKT. (G) Relative levels of p-AKT/AKT in (F) from three independent experiments. (H) Primary hepatocytes were transfected with Gaq-siRNA for 48 h, then cultured with DMT (20 µM) for 3.5 h, followed by co-incubation with glucagon (10 nM) for 0.5 h, and finally collected for Western blot assay with antibodies against p-AKT and AKT. (I) Relative levels of p-AKT/AKT in (H) from three independent experiments. (J) Primary hepatocytes were pre-incubated with DMT (20 µM) for 3 h, followed by co-incubation with suramin (50, 100 µM) for 1 h, finally collected for Western blot assay with antibodies against p-AKT and AKT. (K) Relative levels of p-AKT/AKT in (J) from three independent experiments. All data were obtained from three independent experiments and presented as means ± S.E.M. (*P<0.05, **P<0.01, ***P<0.001; ns, no significance).
DMT inhibits hepatic gluconeogenesis

Ga	extsubscript{q} protein is involved in DMT-regulated AKT phosphorylation Given that Ga	extsubscript{q} protein inactivates adenyl cyclase and reduces intracellular cAMP level (Li et al. 2013), and it mediates insulin-regulated AKT phosphorylation to inhibit gluconeogenesis (Yang et al. 2013), we wondered whether DMT exhibited capability in regulating Ga	extsubscript{q} signaling. As indicated in Fig. 6A, B and C, DMT had no effect on intracellular cAMP level in the absence or presence of either glucagon or FSK. These results thereby implied that DMT was not a Ga	extsubscript{q} signaling regulator. Furthermore, Ga	extsubscript{q} protein inhibitor pertussis toxin (PTX) (Gao & Jacobson 2016) did not influence the DMT-induced AKT phosphorylation (Fig. 6D and E), further demonstrating that the DMT-increased AKT phosphorylation was independent of Ga	extsubscript{q} signaling. Considering that Ga	extsubscript{q}-activated PLC rapidly hydrolyzes PIP2 to increase IP3 and Ca	extsuperscript{2+} levels (Litosch 2016), we next investigated whether Ga	extsubscript{q} protein participated in the regulation of DMT against AKT phosphorylation. As shown in Fig. 6F, G, H and I, RNA interference mediated by Ga	extsubscript{q} siRNA remarkably reduced Ga	extsubscript{q} protein expression and largely resisted DMT-stimulated AKT phosphorylation in hepatocytes transfected with siRNA for 48 h in the absence or presence of glucagon. Therefore, these results demonstrated Ga	extsubscript{q} protein is involved in DMT-regulated AKT phosphorylation.

It is noted that the first member of family with sequence similarity 3 (FAM3A)-induced AKT phosphorylation could be blocked by Gaq-coupled GPCR P2Y receptor antagonist suramin (Wang et al. 2014). However, in our current research, incubation with suramin rendered no influence on the regulation of DMT against AKT phosphorylation (Fig. 6J and K), exhibiting that DMT might directly target Gaq protein or couple to other Gaq-coupledGPCRs except P2Y receptor to regulate Gaq signaling pathway.

Taken together, the above results implied that DMT regulates hepatic gluconeogenesis involving Gaq/PLC/IP3R pathway. It is tentatively suggested that DMT may function as a Gaq signaling regulator to increase intracellular Ca	extsuperscript{2+} level through Gaq/PLC/IP3R pathway and suppress hepatic gluconeogenesis through Ca	extsuperscript{2+}/CaM/PI3K/AKT/FOXO1 pathway.

DMT ameliorates hyperglycemia in db/db mice

As DMT has been determined to be capable of inhibiting hepatic gluconeogenesis, we next examined its capability in ameliorating hyperglycemia against type 2 diabetic model mice. In the assay, 8-week-old db/db male mice were divided into 2 groups and administered with either DMT (25 mg/kg) or vehicle by intraperitoneal

Figure 7

DMT ameliorates hyperglycemia in db/db mice. (A) Fasting blood glucose levels were detected weekly in db/db mouse with treatment of DMT (25 mg/kg/day) (n = 8). (B) HbA1c levels were determined in db/db mouse after treatment with DMT for 5 weeks (n = 8). (C) OGTT assay was performed in db/db mouse after treatment with DMT (25 mg/kg/day) for 4 weeks (n = 8). (D) AUC result of OGTT in (C). (E) PTT assay was performed in db/db mouse after treatment with DMT (25 mg/kg/day) for 5 weeks (n = 8). (F) AUC result of PTT in (E). (G) The body weight of db/db mouse with treatment of DMT (25 mg/kg/day) was recorded twice per week (n = 8). (H) Serum ALT and AST levels were determined in db/db mouse after treatment with DMT for 5 weeks (n = 8). All data were presented as means ± s.e.m. (*P < 0.05, ***P < 0.001; ns, no significance).
Figure 8
DMT suppresses gluconeogenesis and activates AKT/FOXO1 pathway in db/db mice. (A) Liver tissues of db/db mice with treatment of DMT (25 mg/kg/day) for 5 weeks were used to perform q-PCR assay to detect the mRNA levels of G6pase, Pepck, Fbp2 and Pgc1α (n=8). (B) Liver tissues of db/db mice with treatment of DMT (25 mg/kg/day) for 5 weeks were used to perform Western blot assay with corresponding antibodies (n=4). (C and D) Relative protein levels of G6Pase/GAPDH (C) and PEPCK/GAPDH (D) in (B). (E) Liver tissues of db/db mice with treatment of DMT (25 mg/kg/day) for 5 weeks were used to perform Western blot assay with antibodies against p-AKT and AKT (n=4). (F) Relative levels of p-AKT/AKT in (E). (G) Liver tissues of db/db mice with treatment of DMT (25 mg/kg/day) for 5 weeks were used to perform Western blot assay with antibodies against p-FOXO1 and FOXO1 (n=4). (H) Relative levels of p-FOXO1/FOXO1 in (G). (I) A proposed signaling pathway interpreting the regulation of DMT against hepatic gluconeogenesis. DMT activated Gαq signaling to increase intracellular Ca2+ level through Gαq/PLC/IP3R pathway. The increased Ca2+ bound to CaM and regulated the PI3K/AKT pathway to stimulate phosphorylation of transcription factor FOXO1 and suppress gluconeogenesis through inhibiting gluconeogenic genes transcription. All data were presented as means±s.e.m. (*P<0.05, **P<0.01).
injection for 5 weeks. The results demonstrated that DMT treatment reduced the fasting blood glucose (Fig. 7A) and HbA1c (Fig. 7B) levels and improved the glucose tolerance (Fig. 7C and D) and pyruvate tolerance (Fig. 7E and F). Additionally, the results in Fig. 7G and H showed that DMT administration did not obviously change body weight, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels of plasma in db/db mice, suggesting that administration of DMT (25 mg/kg/day) for 5 weeks exerted no apparently hepatic toxicity of db/db mice. All the results thus indicated that DMT ameliorates hyperglycemia in db/db mice.

**DMT suppresses hepatic gluconeogenesis and activates AKT/FOXO1 pathway in db/db mice**

Given that DMT could inhibit gluconeogenesis in hepatocytes and improve pyruvate tolerance in vivo, we next evaluated its activity in suppressing gluconeogenesis in the liver tissues of db/db mice. As shown in Fig. 8A, B, C and D, DMT administration inhibited mRNA levels of G6pase, Pepeck, Fbp2 and Pgc1α and reduced protein expressions of G6pase and PEPCK. In view of the cell-based result that AKT/FOXO1 pathway was involved in DMT-mediated hepatic gluconeogenesis, we also evaluated the regulation of DMT against this pathway in vivo. The results demonstrated that DMT treatment increased the phosphorylation levels of AKT and FOXO1 (Fig. 8E, F, G and H), which was consistent with the cell-based results (Figs 2B and 3B). All results suggested that DMT suppresses hepatic gluconeogenesis and activates AKT/FOXO1 pathway in db/db mice.

**Discussion**

T2DM is a chronic metabolic disease bringing heavy burdens to societies (Zimmet et al. 2001). Although the underlying pathological basis of T2DM is obscure, continuous activated gluconeogenesis increases HGP and elevates blood glucose level in T2DM (Yoon et al. 2001, Inzucchi et al. 2012), and reducing HGP is believed to be an ideal strategy for reducing blood glucose (Zheng et al. 2015). It has been found that metformin efficiently improves hyperglycemia primarily through suppressing gluconeogenesis (Rena et al. 2013), but lactic acidosis is one of its side effects, which has limited the application of metformin (Li et al. 2016, Omar et al. 2016). Here, we found that DMT was effective in suppressing HGP and inhibiting gluconeogenic genes transcription and in vivo assay results demonstrated that DMT could improve glucose homeostasis. The reduction of gluconeogenesis evoked by metformin may be a result of an inhibition of mitochondrial respiratory chain complex I, AMP deaminase and mitochondrial glycerophosphate dehydrogenase (An & He 2016). However, DMT-inhibited gluconeogenesis involves PI3K/AKT/FOXO1 signaling pathway regulated by Gαq/PLC/IP3R/Ca2+ axis, and DMT did not increase the lactate production in hepatocytes and serum (Supplementary Fig. 1E and F). All results have highlighted the potency of targeting gluconeogenesis inhibition in the treatment of T2DM and the potential of DMT as an anti-T2DM drug lead compound. The small molecule DMT was determined by cell-based screening against the lab in-house compound library partly purchased from SPECS commercial company. To date, there is no report on the bioactivity of DMT, although DMT shares the similar structural skeleton to that of thienopyridine, whose derivatives exhibit anti-bacterial, anti-fungal and antitumoral activities (Hayakawa et al. 2004, Khidre et al. 2011). Our current work has thus firstly expanded the pharmacological applications of this kind of compounds in suppressing hepatic gluconeogenesis and potentially treating T2DM.

It is well known that intracellular free Ca2+ comes from extracellular Ca2+ influx and/or the release from Ca2+ storages. Mitochondria and ER are the storehouses of Ca2+ in charge of accumulating and releasing Ca2+ under certain cellular events (Pinto et al. 2015). Activated Gαq protein causes PLC activation leading to the generation of IP3 and the release of Ca2+ from ER (Hubbard & Hepler 2006, Li et al. 2013). Gqα protein is necessary for the insulin-induced translocation of glucose transporter 4 (GLUT4) in 3T3-L1 adipocytes (Sanchez-Fernandez et al. 2014). Unfortunately, the metabolic roles of hepatic Gαq-coupled GPCRs are less well defined in vivo. Reports demonstrated that hepatocytes express several Gαq-coupled GPCRs that are also expressed in many other tissues (Regard et al. 2008). It is reported that selectively stimulating Gαq-linked GPCR in hepatocytes may increase blood glucose level and impair glucose tolerance (Li et al. 2013). Activation of P2Y receptor inhibits hepatic gluconeogenesis and lipogenesis involving PI3K/AKT signaling pathway in a CaM-dependent manner (Wang et al. 2014). Gluconeogenesis and glycogenolysis increase in the mice with deficiency of the ghrelin, an endogenous ligand of ghrelin receptor belonging to a Gαq-coupled GPCR (Chacko et al. 2012, Damian et al. 2015).
We herein found that DMT, as a Gaq signaling regulator, suppressed hepatic gluconeogenesis through Gaq/PLC/IP3R-mediated Ca2+/Cam/PI3K/AKT/FOXO1 pathway. In the previous work, the Gaq-linked designer receptor overexpressed in transgenic mouse was a mutant M3 muscarinic receptor, and V1b vasopressin receptor expression was enhanced in ob/ob mice (Li et al. 2013). To our knowledge, M3 muscarinic receptor and V1b vasopressin receptor belong to Gaq-coupledGPCRs, but they are not representative of all Gaq-coupled GPCRs or endogenous Gaq signaling (Li et al. 2009). In our current study, we used RNA interference technology to knockdown endogenous Gaq protein finding that the regulation of DMT against AKT phosphorylation was dependent on Gaq protein. Our results tentatively suppose that activation of Gaq signaling probably suppresses hepatic gluconeogenesis in line with another published report (Wang et al. 2014).

It has been reported that effects of Gaq on AKT varies depending on cell types. For example, activated Gaq inhibited PI3K/AKT pathway independently of PLC in 293 cells (Ballou et al. 2003), and Gaq-coupled receptors such as bradykinin, thrombin and carbachol increase AKT phosphorylation in different cells (Sanchez-Fernandez et al. 2014). Additionally, Gaq inhibitor UBO-QIC inhibits AKT signaling stimulated by P2Y receptor (Gao & Jacobson 2016). In our current research, RNA interference of Gaq apparently abolished the DMT-stimulated AKT phosphorylation, and further investigation suggested that Gaq/PLC/IP3R signaling might be involved in the DMT-inhibited hepatic gluconeogenesis through Ca2+/Cam/PI3K/AKT/FOXO1 pathway, while P2Y receptor was not involved in the regulation of DMT. Although the specific Gaq-coupled GPCR involved in DMT regulation or whether DMT directly activates Gaq is still needed to be further investigated, DMT as a small-molecule

### Table 1
Plasma concentrations (ng/mL) and pharmacokinetic parameters of DMT in C57BL/6 mice treated with DMT (10 mg/kg) by intraperitoneal injection.

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Mouse-1</th>
<th>Mouse-2</th>
<th>Mouse-3</th>
<th>Mean</th>
<th>s.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.08</td>
<td>3384.2</td>
<td>3185.6</td>
<td>3233.3</td>
<td>3267.7</td>
<td>103.7</td>
</tr>
<tr>
<td>0.25</td>
<td>8493.4</td>
<td>9872.4</td>
<td>7908.3</td>
<td>8758.0</td>
<td>1008.4</td>
</tr>
<tr>
<td>0.5</td>
<td>15,709.3</td>
<td>14,885.1</td>
<td>12,532.6</td>
<td>14,375.7</td>
<td>1648.5</td>
</tr>
<tr>
<td>1</td>
<td>18,329.7</td>
<td>20,930.8</td>
<td>16,829.4</td>
<td>18,696.6</td>
<td>2075.2</td>
</tr>
<tr>
<td>2</td>
<td>21,660.3</td>
<td>25,529.5</td>
<td>20,455.7</td>
<td>22,541.8</td>
<td>2658.9</td>
</tr>
<tr>
<td>4</td>
<td>22,872.7</td>
<td>26,921.8</td>
<td>19,348.8</td>
<td>23,047.8</td>
<td>3789.5</td>
</tr>
<tr>
<td>8</td>
<td>18,588.2</td>
<td>24,892.2</td>
<td>19231.8</td>
<td>20,904.1</td>
<td>3468.8</td>
</tr>
<tr>
<td>24</td>
<td>17,081.6</td>
<td>15,923.2</td>
<td>15,310.7</td>
<td>16,105.2</td>
<td>899.4</td>
</tr>
<tr>
<td>48</td>
<td>13,902.1</td>
<td>15,142.7</td>
<td>14,363.4</td>
<td>14,469.4</td>
<td>627.1</td>
</tr>
<tr>
<td>72</td>
<td>9809.7</td>
<td>13,361.0</td>
<td>13,149.4</td>
<td>12,106.7</td>
<td>1992.1</td>
</tr>
<tr>
<td>168</td>
<td>7707.1</td>
<td>7235.4</td>
<td>7269.0</td>
<td>7403.8</td>
<td>263.2</td>
</tr>
<tr>
<td>HL_Lambda_z (T1/2, h)</td>
<td>124.11</td>
<td>111.41</td>
<td>129.01</td>
<td>121.51</td>
<td>9.08</td>
</tr>
<tr>
<td>T_max (h)</td>
<td>4.00</td>
<td>4.00</td>
<td>2.00</td>
<td>3.33</td>
<td>1.15</td>
</tr>
<tr>
<td>C_max (ng/mL)</td>
<td>22,872.7</td>
<td>26,921.8</td>
<td>20,435.7</td>
<td>23,410.07</td>
<td>3276.27</td>
</tr>
<tr>
<td>AUCinf (h*ng/mL)</td>
<td>1,939,043.7</td>
<td>2,218,655.3</td>
<td>2,086,094.6</td>
<td>2,081,264.56</td>
<td>139,868.17</td>
</tr>
<tr>
<td>AUC_{inf,pred} (h*ng/mL)</td>
<td>3,213,734.2</td>
<td>3,384,747.7</td>
<td>3,467,947.9</td>
<td>3,355,476.61</td>
<td>129,609.97</td>
</tr>
<tr>
<td>MRT_{last} (h)</td>
<td>67.34</td>
<td>64.71</td>
<td>67.67</td>
<td>66.57</td>
<td>1.62</td>
</tr>
<tr>
<td>Vz, F_{pred} (U/kg)</td>
<td>0.56</td>
<td>0.47</td>
<td>0.54</td>
<td>0.52</td>
<td>0.04</td>
</tr>
<tr>
<td>Cl, F_{pred} (U/h/kg)</td>
<td>0.0031</td>
<td>0.0030</td>
<td>0.0029</td>
<td>0.0030</td>
<td>0.0001</td>
</tr>
<tr>
<td>λz calculation time range (h)</td>
<td>8–168</td>
<td>48–168</td>
<td>24–168</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

### Table 2
Plasma concentrations (ng/mL) and liver/pancreas/gastrocnemius muscle concentrations (ng/g) of DMT in C57BL/6 mice treated with DMT (10 mg/kg) for 4 h by intraperitoneal injection.

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Mice (n=4)</th>
<th>Plasma (ng/mL)</th>
<th>Liver (ng/g)</th>
<th>Pancreas (ng/g)</th>
<th>Muscle (ng/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Mouse-1</td>
<td>47,949.8</td>
<td>16,482.4</td>
<td>8893.5</td>
<td>1543.3</td>
</tr>
<tr>
<td></td>
<td>Mouse-2</td>
<td>47,486.1</td>
<td>12,393.7</td>
<td>6043.4</td>
<td>1289.2</td>
</tr>
<tr>
<td></td>
<td>Mouse-3</td>
<td>40,777.3</td>
<td>12,665.4</td>
<td>6801.3</td>
<td>1312.3</td>
</tr>
<tr>
<td></td>
<td>Mouse-4</td>
<td>43,640.9</td>
<td>16,825.6</td>
<td>7509.0</td>
<td>1411.3</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>44,963.5</td>
<td>14,591.8</td>
<td>7309.8</td>
<td>1389.0</td>
</tr>
<tr>
<td>s.d.</td>
<td></td>
<td>3393.9</td>
<td>2387.9</td>
<td>1212.0</td>
<td>115.7</td>
</tr>
</tbody>
</table>
probe may better understand Gaq signaling and hepatic gluconeogenesis. Since GPCRs are determined to be targets of various pharmaceutical drugs and G proteins can be regulated by GPCRs, small molecules that directly modulate G proteins have become promising therapeutic agents (Nishimura et al. 2010). In addition, structural biology might help illustrate the underlying modulatory basis between small molecules and targeted GPCRs or G proteins and highlight the potential of the agents in drug design (Nishimura et al. 2010). Preliminary pharmacokinetic study implied that DMT exerted a quick absorption and a slow elimination in mice by intraperitoneal injection, and the maximum plasma concentration turned up around 4 h with a half-life around 120 h (Table 1 and Supplementary Fig. 1D). Tissue distribution assay indicated that DMT was distributed in several main organs related to glucose homeostasis, including liver, pancreas and gastrocnemius muscle (Table 2). It is noted that the table did not involve DMT content in adipose tissue, because of some difficulties in extracting the adipose tissue from abdominal cavity in the assay, although DMT content investigation in adipose tissue should be further supplemented in DMT-based drug discovery.

In conclusion, we have identified that small-molecule DMT suppressed hepatic gluconeogenesis involving Gaq/PLC/IP3R-mediated Ca²⁺/CaM/PK3/akt/FOXO1 pathway. To our knowledge, DMT might be the first reported small molecule as a Gaq signaling receptor function in hepatic gluconeogenesis inhibition. Our findings have also highlighted the potential of DMT in the treatment of T2DM.

Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1530/JME-17-0121.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the National Natural Science Foundation of China (grant number 81473141), NSFC-TRF collaboration projects (grant numbers 81473141, 81670229), Key Laboratory of Receptor Research of the Chinese Academy of Sciences (grant number SIMM1606Y2Z-04), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine).

References


Hayakawa I, Shiyo R, Agatsuma T, Furukawa H & Sugano Y 2004 Thienopyridine and benzofuran derivatives as potent anti-tumor


Rh SY & Kim UH 2015 CD38-mediated Ca2+ signaling contributes to glucagon-induced hepatic gluconeogenesis. Scientific Reports 5 10741. (doi:10.1038/srep10741)


